ZTS — Zoetis Inc.

Market sentiment is bearish because investors are focused on the FY2026 guidance cut, flat Q2 reported revenue, soft veterinary visit volumes, pet-owner price sensitivity, and post-patent competition in dermatology and parasiticide. The stock is down roughly 50% from its high, analyst consensus is Hold with a $87.33 average target, and the price is deeply below its 200-day moving average.

This is a genuine downward inflection, not a one-quarter blip. Revenue growth decelerated from +4.2% YoY in Q2 2025 to +0.3% in Q2 2026, with Q1 2026 at +1.9%. Operating income swung from +9.2% YoY in Q2 2025 to -5.3% in Q2 2026, and net income turned to -3.8% YoY. Margins remain strong—Q2 2026 operating margin was ~38.0% and gross margin ~72.7%—but Q2 2025's 40.2% operating margin has compressed, and the FY2026 guidance explicitly points to organic revenue decline. The trend is visibly rolling over.

Cheap vs. its own history: trailing P/E is 12.34 and P/S is 3.31 versus 5-year averages of 35.78 and 9.59. But this is a 'show-me' cheap. With consensus next-year EPS around $6.25, the stock trades at roughly 12.0x forward earnings and offers a ~2.7% dividend yield. PEG of 2.76 and flat-to-negative near-term growth mean it is not cheap relative to its current growth rate; the market is discounting continued deterioration. It is fairly valued to cheap only if the demand slump is cyclical rather than permanent.

The stock has re-rated from a ~30x+ growth multiple to ~12x trailing earnings while EPS has not collapsed—TTM EPS is ~$6.26 and consensus next-year EPS is ~$6.25. In other words, price has fallen far more than reported earnings so far. If forward estimates hold, the stock is pricing in meaningful earnings downside that hasn't materialized yet; if Q3/Q4 confirm the lowered guidance is the floor, multiple normalization toward $85-$90 is plausible. If estimates get cut below $6, the 12x P/E becomes fair rather than cheap.

As of 2026-08-27, RSI(14) is 47.53—neutral, not oversold—and price is only 0.7% below its 20-day and 0.9% below its 50-day, but 28.1% below its 200-day. This is a downtrend that has flattened in the $71-$77 zone, with no confirmed reversal yet. A reclaim of the 50-day would be the first constructive sign; a decisive break below $71 would open further downside.

• Persistent inflation / cost-of-living pressure on pet owners is reducing vet visit frequency and causing trade-down from premium dermatology and parasiticide products.
• Post-patent-expiry competition (e.g., oclacitinib) from Elanco, Virbac, and others is structurally pressuring high-margin companion-animal franchises.
• Interest rates and balance-sheet leverage: with long-term debt of ~$9.0B and equity down to ~$3.1B, higher-for-longer rates make buyback-heavy capital returns less compelling and raise debt-service costs.
• Consumer discretionary weakness is turning a historically defensive animal-health business more cyclical, especially in U.S. pet care.
• International and livestock segments provide partial diversification, but not enough to offset U.S. companion-animal softness.

• Q3 2026 earnings (expected around Nov 3, 2026): whether management holds the lowered FY2026 guidance floor or cuts again.
• Pipeline/regulatory milestones: U.S. approval and launch progress on Lenivia (2027 window) and life-cycle management of Librela/Solensia monoclonal antibodies.
• Stabilization or recovery in veterinary visit volumes and pet-owner spending, which would reverse the current trade-down trend.
• Capital returns: the 2.74% dividend yield plus buybacks provide a valuation floor if FCF stays near $2.4B.

• Further guidance cuts and estimate revisions if younger pet owners continue to defer care and trade down on high-margin therapeutics.
• Market share erosion in dermatology and parasiticide after patent expirations, causing operating margin compression in Zoetis's most profitable franchises.
• High leverage and shrinking equity: long-term debt is ~$9.05B, net debt is ~$7.6B, and debt-to-equity is ~2.94; a prolonged downturn would reduce financial flexibility.
• Regulatory or pipeline setbacks delaying new blockbuster growth and extending the current no-growth period.

At $75, ZTS is a high-quality, high-margin animal-health franchise being priced as a no-growth cash cow. Near-term fundamentals have genuinely deteriorated—guidance was cut, and competition is biting—but the market has already de-rated the stock more than earnings have fallen so far. For a long-term investor, this is closer to 'wait for stabilization or build a small position' than a clear buy; for momentum, the trend is still down. Net lean: Neutral, with a slightly favorable valuation bias.

Calculated by applying an 18.5x EV/FCF multiple to trailing free cash flow of ~$2.37B, subtracting net debt of ~$7.57B, and dividing by ~419M shares, yielding ~$86.36. That multiple is justified for a high-quality (21.5% ROIC, ~71% gross margin) but currently no-growth animal-health franchise, and it cross-checks to roughly 13.8x forward EPS of $6.25.